Balloon angioplasty is now a well established minimally invasive surgical technique. It involves introducing an inflatable catheter into the lumen of coronary or femoral arteries to permanently dilate the bore of the occluded vessel to allow more efficient blood flow. Regrettably, in a third to a half of patients restenosis (reduction of the size of the lumen) occurs due to the proliferation of smooth muscle cells in the vessel wall (the intima) to form a thickened layer called a neointima.
It is generally accepted that this process is a form of wound healing response, probably initiated due to damage to the endothelial cell layer, and to a reaction to the physical extension of the intimal muscle layer. Although a complex process, wound healing is controlled, at least in part, by the production of growth factors, sometimes acting in a paracrine manner (being synthesised by one cell type and acting on another close by) or by an autocrine process (being produced by and acting on the same cell). These systems have the dual role of controlling cell proliferation during development as well as their activity in tissue repair following acute or chronic damage. One large superfamily of such molecules is characterised by acting through receptors which possess protein tyrosine kinase activity. These systems control cell survival, death, division and motility through regulating a complex set of intracellular signal transduction systems affecting gene expression and cytoskeletal structure.
Several types of these factors and their receptors have been implicated in the process of restenosis following percutaneous angioplasty and are thus targets for pharmaceutical intervention and, most recently, for gene therapy. In this issue Deguchi et al 1 report the successful use of an adenovirus-mediated genetic treatment targeted at platelet-derived growth factor in a balloon-injured rat carotid artery model. PDGF released by platelet degranulation has for some time been implicated in atherosclerosis, 2 but it is clearly also expressed by smooth muscle cells where it may be involved in intimal hyperplasia.
There are several strategies available to inhibit signalling by receptor tyrosine kinases. First, one can reduce the effective concentration of the ligand. Ferns et al 3 showed eight years ago that daily injection of an antibody to PDGF which neutralised its activity partially prevented neointima formation in athymic rats. The present work by Deguchi takes another approach. Here, an adenoviral vector has been used to transfer a fragment of the PDGF receptor into the injured arterial wall. The truncated extracellular domain of the PDGF receptor had previously been shown to bind PDGF and to inhibit its ability to interact productively with its receptor in cultured smooth muscle cells. The vector was administered immediately after injury or five days following angioplasty. The transfection efficiency was determined by LacZ expression and was found to be much higher at the latter time where more than 90% of neointimal cells and some medial SMC's were positive. Various virus titres were tested and 10 10 p.f.u./ml was found to be optimal and RTPCR analysis showed expression of the truncated receptors. Critically, in arteries receiving this treatment they found that the intimal area was reduced relative to controls by 57%. The PDGF receptor was inhibited as assessed by its phosphorylation state but there was no effect on tyrosine phosphorylation of the epidermal growth factor receptor. Finally, in confirmation of these results the treatment reduced cell proliferation in the intima, measured by BrdU incorporation, by 60% at 10 days.
The fundamental difference between the use of antibodies and the gene therapy strategy is that the latter is a once-only local treatment. The authors point out, however, that adjacent cells can none the less be affected as the truncated receptor is secreted from the cells. Soluble inhibitors have the advantage that they may be orally available and can be used repeatedly but they have the potential problem of nonspecific toxicity and specific toxicity through unwanted inhibition of the PDGF receptor at other sites. A pharmaceutical approach has been supported with a meta-analysis of trapidil (a PDGF inhibitor), from three human trials, showing a reduction by 50% of the coronary restenosis rate. 4 Similarly, two anti-allergic drugs, tranilast and perimolast, have shown recent promise and may act through suppression of TGF-␤1. 5, 6 Positive results have also been reported with blockade of thrombin, 7 angiotensin 11, 8 c-myc and c-myb 9 activity. However, molecularly directed treatments will have to perform well when compared with the latest results using vascular brachytherapy for prevention of restenosis. The PREVENT trial (proliferation reduction with vascular energy trial) involving the use of a beta emitter ( 32 P) delivered to the site of angioplasty on a wire-tipped catheter is now completed 10 and the SCRIPPS trial (Scripps coronary radiation to inhibit proliferation poststenting) 11 data have now been published. In the latter study, catheter-based radiation with iridium-192 resulted in only 16.7% of patients experiencing restenosis versus 53.9% of controls. It is an encouraging situation, therefore, in which new approaches to this problem are in competition and it emphasises that growth factor receptor inhibition is of relevance to a number of pathological conditions, and not just to cancer.
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